Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer

被引：39

作者：

Chlebowski, Rowan ^{[1
]}

Cuzick, Jack ^{[2
]}

Amakye, Dereck ^{[3
]}

Bauerfeind, Ingo ^{[4
]}

Buzdar, Aman ^{[5
]}

Chia, Stephen ^{[6
]}

Cutuli, Bruno ^{[7
]}

Linforth, Rick ^{[8
]}

Maass, Nicolai ^{[9
]}

Noguchi, Shinzaburo ^{[10
]}

Robidoux, Andre ^{[11
]}

Verma, Sunil ^{[12
]}

Hadji, Peyman ^{[13
]}

机构：

[1] Harbor UCLA, Los Angeles Biomed Res Inst, Med Ctr, Torrance, CA 90502 USA

[2] Univ London, Wolfson Inst Preventat Med, London, England

[3] AstraZeneca, Macclesfield, Cheshire, England

[4] Univ Munich, Klinikum Landshut, Munich, Germany

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[7] Polyclin Courlancy, Reims, France

[8] St Lukes Hosp, Bradford BD5 0NA, W Yorkshire, England

[9] Rhein Westfal TH Aachen, Aachen, Germany

[10] Osaka Univ, Grad Sch Med, Osaka, Japan

[11] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada

[12] Univ Toronto, Toronto, ON M5S 1A1, Canada

[13] Univ Marburg, Marburg, Germany

来源：

BREAST | 2009年 / 18卷

关键词：

Aromatase inhibitor; Breast cancer; Adjuvant therapy; Duration of treatment; Endocrine therapy; BONE-MINERAL DENSITY; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; RETROSPECTIVE ANALYSIS; ENDOCRINE THERAPY; RISK-FACTORS; ENDOMETRIAL CANCER; TAMOXIFEN THERAPY; AMERICAN SOCIETY; TUMOR RECURRENCE;

D O I：

10.1016/S0960-9776(09)70002-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：S1 / S11

页数：11

共 91 条

[1] Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program [J].

Aapro, M. .

BREAST, 2006, 15 :S30-S40

[2]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[3]

ABRAHAM JE, 2008, SAN ANT BREAST CANC

[4]

BERG JS, 1993, ANN PHARMACOTHER, V27, pS1

[5] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer [J].

Bergman, L ;

Beelen, MLR ;

Gallee, MPW ;

Hollema, H ;

Benraadt, J ;

van Leeuwen, FE .

LANCET, 2000, 356 (9233) :881-887

[6]

BRIOT K, 2008, BREAST CANC

[7] Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole [J].

Brufsky, Adam ;

Bundred, Nigel ;

Coleman, Robert ;

Lambert-Falls, Rosemary ;

Mena, Raul ;

Hadji, Peyman ;

Jin, Lixian ;

Schenk, Nora ;

Ericson, Solveig ;

Perez, Edith A. .

ONCOLOGIST, 2008, 13 (05) :503-514

[8] Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial [J].

Buzdar, A. ;

Howell, A. ;

Cuzick, J. ;

Wale, C. ;

Distler, W. ;

Hoctin-Boes, G. ;

Houghton, J. ;

Locker, G. Y. ;

Nabholtz, J. M. .

LANCET ONCOLOGY, 2006, 7 (08) :633-643

[9] Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up [J].

Buzdar, A. U. ;

Cuzick, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[10] Clinical risk factors for fractures in multi-ethnic women: The women's health initiative [J].

Cauley, Jane A. ;

Wu, LieLing ;

Wampler, Nina S. ;

Barnhart, Janice M. ;

Allison, Matthew ;

Chen, Zhao ;

Jackson, Rebecca ;

Robbins, John .

JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (11) :1816-1826

← 1 2 3 4 5 6 7 8 9 10 →